A steady flow of promising drug candidates from the discovery pipeline ensures an ongoing and sustainable search for tomorrow's TB treatments. The TB Alliance closely coordinates and collaborates with TB drug discovery programs globally to deliver new drug candidates, optimize resource utilization and advance promising projects that might otherwise fail to progress.
With this objective in mind, the TB Alliance manages a robust portfolio of drug discovery projects that include screening against validated TB drug targets, generating new chemical lead series, and optimizing promising lead series to identify development candidates.
In partnership with Johns Hopkins University, the TB Alliance is also engaging pharmaceutical companies, funders, and global regulatory bodies to support the innovative approach of testing new TB drug candidates together early in the drug development process. This collaborative effort will screen potential drug combinations using predicative animal models to identify the most promising TB regimens at the preclinical stage.
Forging global partnerships The TB Alliance has partnered with some of the world's leading drug developers to jointly manage TB drug discovery portfolios consisting of multiple TB drug discovery programs. This approach aligns target product profiles, makes efficient use of resources, and leverages the expertise and contributions of each partner to have a significant impact on the global discovery portfolio. The TB Alliance jointly manages TB drug discovery portfolios with AstraZeneca, GlaxoSmithKline, and the Novartis Institute for Tropical Diseases.
For more information on partnering opportunities, please visit our FAQs.